To evaluate the effects of oncogenic activation in the PI3K pathway on anti-HER2 therapy, we performed in vitro proliferation assays using a HER2 inhibitor, lapatinib, in HER2+ breast cancer cell lines. Here, PIK3CA is linked to breast cancer.